Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Rapid progression of colonic mucinous adenocarcinoma with immunosuppressive condition: A case report and review of literature
Youhei Koseki, Kenya Kamimura, Yuto Tanaka, Marina Ohkoshi-Yamada, Qiliang Zhou, Yoshifumi Matsumoto, Takeshi Mizusawa, Hiroki Sato, Akira Sakamaki, Hajime Umezu, Junji Yokoyama, Shuji Terai
Youhei Koseki, Kenya Kamimura, Yuto Tanaka, Marina Ohkoshi-Yamada, Takeshi Mizusawa, Hiroki Sato, Akira Sakamaki, Junji Yokoyama, Shuji Terai, Division of Gastroenterology and Hepatology, Niigata University, Niigata 9518510, Japan
Kenya Kamimura, Department of General Medicine, Niigata University, Niigata 9518510, Japan
Qiliang Zhou, Yoshifumi Matsumoto, Department of Medical Oncology, Niigata University, Niigata 9518510, Japan
Hajime Umezu, Division of Pathology, Niigata University, Niigata 9518510, Japan
Author contributions: Koseki Y, Kamimura K and Terai S wrote the manuscript; Tanaka Y, Ohkoshi-Yamada M, Zhou Q, Matsumoto Y, Mizusawa T, Sato H, Sakamaki A and Yokoyama J treated patients; Umezu H performed histological analysis; all authors read and approved the final version of the manuscript.
Informed consent statement: A study participant provided informed written consent about personal and medical data collection prior to study enrolment.
Conflict-of-interest statement: The authors declare that they have no current financial arrangement or affiliation with any organization that may have a direct influence on their work.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
http://creativecommons.org/Licenses/by-nc/4.0/ Corresponding author: Kenya Kamimura, MD, PhD, Professor, Department of General Medicine, Niigata University, 1-757, Asahimachi do-ri, Niigata 9518510, Japan. kenya-k@med.niigata-u.ac.jp
Received: April 14, 2021
Peer-review started: April 14, 2021
First decision: June 25, 2021
Revised: June 29, 2021
Accepted: September 8, 2021
Article in press: September 8, 2021
Published online: October 26, 2021
BACKGROUND
Colorectal mucinous adenocarcinoma is a rare subtype of colorectal cancer and is characterized by an abundance of mucin in the tumor. In addition, the colorectal mucinous adenocarcinoma often demonstrates poor differentiation in the histology of tumor cells and poor prognosis compared with those with adenocarcinoma. Here, we present the case of a young woman with colonic mucinous adenocarcinoma showing significantly rapid progression within four months of immunosuppressant therapy for Henoch–Schönlein purpura.
CASE SUMMARY
Here we report a rare case of ascending colon mucinous adenocarcinoma with lymph node and liver metastases which developed and progressed rapidly within four months during the treatment of Henoch–Schönlein purpura using corticosteroids. The systemic screening examinations showed no tumors before the immunosuppressant therapy. Fortunately, the patient was successfully treated with chemotherapy.
CONCLUSION
While no direct evidence that the immunosuppressants accelerated the tumor development, the case presenta tion and review of the literature demonstrated that surveillance for malignancies before and during treatment with immunosuppressive agents is essential.
Core Tip: Here, we report a rare case of ascending colon mucinous adenocarcinoma with lymph node and liver metastases that developed within four months of immunosuppressant therapy. The information obtained from this case and from a review of the relevant literature highlights the importance of surveillance for malignancies before and during immunosuppressive treatment.
